Labcorp (NYSE:LH) EVP Bryan Vaughn Sells 234 Shares of Stock

Labcorp Holdings Inc. (NYSE:LH) EVP Bryan Vaughn sold 234 shares of Labcorp stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $286.19, for a total value of $66,968.46. Following the completion of the sale, the executive vice president directly owned 6,746 shares of the company’s stock, valued at approximately $1,930,637.74. This represents a 3.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Labcorp Stock Up 1.6%

Shares of NYSE LH opened at $288.89 on Tuesday. The stock has a market capitalization of $23.69 billion, a PE ratio of 25.56, a P/E/G ratio of 2.01 and a beta of 0.89. The company has a quick ratio of 1.54, a current ratio of 1.73 and a debt-to-equity ratio of 0.68. The firm has a fifty day moving average of $262.63 and a 200-day moving average of $266.45. Labcorp Holdings Inc. has a 52-week low of $241.81 and a 52-week high of $293.72.

Labcorp (NYSE:LH) last released its quarterly earnings data on Thursday, April 30th. The medical research company reported $4.25 EPS for the quarter, topping analysts’ consensus estimates of $4.09 by $0.16. Labcorp had a return on equity of 16.29% and a net margin of 6.66%.The company had revenue of $3.54 billion for the quarter, compared to the consensus estimate of $3.51 billion. During the same period last year, the business posted $3.84 EPS. The company’s quarterly revenue was up 5.8% compared to the same quarter last year. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. On average, analysts anticipate that Labcorp Holdings Inc. will post 18 EPS for the current year.

Labcorp Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, June 11th. Shareholders of record on Friday, May 29th were given a $0.72 dividend. The ex-dividend date of this dividend was Friday, May 29th. This represents a $2.88 annualized dividend and a yield of 1.0%. Labcorp’s dividend payout ratio (DPR) is 25.51%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Hilltop National Bank boosted its stake in Labcorp by 161.0% in the second quarter. Hilltop National Bank now owns 616 shares of the medical research company’s stock valued at $172,000 after acquiring an additional 380 shares during the period. CX Institutional increased its position in Labcorp by 16.3% in the second quarter. CX Institutional now owns 1,455 shares of the medical research company’s stock worth $407,000 after buying an additional 204 shares during the period. Eastern Bank lifted its position in Labcorp by 1,740.0% in the 2nd quarter. Eastern Bank now owns 276 shares of the medical research company’s stock valued at $77,000 after purchasing an additional 261 shares during the last quarter. Western Wealth Management LLC bought a new position in Labcorp in the 1st quarter worth approximately $130,000. Finally, Parallel Advisors LLC increased its holdings in shares of Labcorp by 11.6% during the first quarter. Parallel Advisors LLC now owns 4,540 shares of the medical research company’s stock valued at $1,212,000 after purchasing an additional 473 shares during the period. 95.94% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Weiss Ratings reiterated a “buy (b-)” rating on shares of Labcorp in a report on Friday, May 8th. Evercore reiterated an “outperform” rating and issued a $300.00 price target on shares of Labcorp in a research note on Wednesday, April 8th. Wall Street Zen lowered Labcorp from a “buy” rating to a “hold” rating in a research note on Saturday, June 13th. Finally, Robert W. Baird set a $334.00 price objective on Labcorp in a report on Friday, May 1st. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Labcorp currently has an average rating of “Moderate Buy” and a consensus price target of $308.00.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.